Company intelligence / Profile preview
Lifex Biolabs
United Stateslifexbiolabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lifex Biolabs is developing innovative small molecule drugs for neurodegenerative and metabolic diseases, with its lead program targeting NR4A2 for Parkinson’s disease currently in preclinical studies
- Therapeutic areas
- OncologyNeurologyEndocrinology
- Modalities
- Small moleculeChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Macrogen (biomarker selection, strategic investment)
Beyond the preview
Go deeper on Lifex Biolabs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lifex Biolabs.